Physician profile
Philip Rubin
NPI 1336253053
$3,760.50
in general payments reported to CMS, 2019-2025
32 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $56.34 · 2021: $217 · 2022: $666 · 2023: $562 · 2024: $651 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $541.17 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $313.59 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| E.R. Squibb & Sons, L.L.C. | $304.09 | 2019-2024 | Opdivo, Augtyro |
| Genzyme Corporation | $285.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $276.99 | 2019-2025 | |
| Abbvie INC. | $213.03 | 2024-2025 | |
| Pfizer INC. | $188.06 | 2019-2024 | |
| Abbott Laboratories | $186.70 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $148.52 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $132.75 | 2022-2023 | Imbruvica, Epkinly |
| Sumitomo Pharma America, INC. | $131.85 | 2023-2025 | Orgovyx |
| Daiichi Sankyo INC. | $107.19 | 2019-2024 | Enhertu |
| Lilly USA, LLC | $94.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.17 | 2019-2024 | Vpriv |
| Bayer Healthcare Pharmaceuticals INC. | $80.11 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $69.84 | 2019 | |
| Celgene Corporation | $69.34 | 2019-2023 | Pomalyst |
| Merck Sharp & Dohme LLC | $65.07 | 2019-2025 | Lynparza, Keytruda |
| Exelixis INC. | $60.55 | 2019 | |
| Eisai INC. | $53.35 | 2025 | |
| Taiho Oncology, INC. | $45.49 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $42.54 | 2019-2020 | |
| Emd Serono, INC. | $41.75 | 2019 | |
| Glaxosmithkline, LLC. | $38.91 | 2025 | Shingrix |
| Tesaro, INC. | $28.00 | 2019 | |
| Incyte Corporation | $25.00 | 2023 | Jakafi |
| Morphosys, US INC. | $23.47 | 2023 | Monjuvi |
| Stemline Therapeutics INC. | $22.94 | 2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $22.57 | 2022 | |
| Amgen INC. | $22.01 | 2023 | Lumakras |
| Octapharma USA, INC. | $20.09 | 2022 | |
| Global Blood Therapeutics, INC. | $14.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.